Be the first to like.

Share

The first gene therapy for an inherited disease in the U.S. is closer to reality than ever before.

Spark Therapeutics is only the second company to pursue an application to the U.S. Food and Drug Administration for such a treatment, but it’s likely to be the first to hit the market.

Speaking at EmTech MIT 2016 on Tuesday, Katherine High, Spark’s cofounder, confirmed that the company is on track to launch its first product next year. The gene therapy, known as SPK-RPE65, targets mutations in people’s eyes that often lead to blindness. Currently, there are no drugs available to treat these disorders, known as inherited retinal dystrophies.

… Read More

Image: Public Domain, https://commons.wikimedia.org/w/index.php?curid=488192

Be the first to like.

Share
MIT Technology Review

Tags: , , , , , , , ,

Leave a Reply